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Abstract
Antimicrobial resistance surveillance data is lacking from many resource-limited settings mainly due to limited laboratory 
testing. Novel culture systems may address some of the limitations of conventional culture media and expand the availability 
of microbiology services. The aims of this study were to evaluate the performance of InTray COLOREX Screen/ESBL and 
Compact Dry for the detection of uropathogens and of extended-spectrum beta-lactamase (ESBL)-producing organisms from 
urine samples. Urines samples were collected from patients presenting with symptoms of urinary tract infection to primary 
care clinics in Harare. Performance of the InTray COLOREX Screen, ESBL and Compact Dry chromogenic media were 
compared to the reference of culture using Brilliance UTI agar and conventional antimicrobial susceptibility testing. A total 
of 414 samples were included in the analysis. Of the included samples, 98 were positive on Brilliance UTI agar and 83 grew 
Enterobacterales. The sensitivities and specificities for Enterobacterales were 89.2% (95% CI 80.4–94.9) and 98.2% (95% 
CI 96.1–99.3) for InTray Screen and 95.2% (95% CI 88.1–98.7) and 99.7% (95% CI 98.3–100) for Compact Dry. Extended-
spectrum beta-lactamases were present in 22 isolates from the Brilliance UTI agar. The sensitivity of the InTray COLOREX 
ESBL culture plates for the detection of ESBL-producing organisms was 95.5% (95% CI 77.2–99.9) and specificity was 99.5% 
(95% CI 98.2–99.9%). Our findings show good performance of the novel culture systems for the detection of uropathogens 
and ESBL-producing organisms. Both systems have several advantages over conventional media and have the potential to 
expand and decentralize laboratory testing.
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Introduction
Antimicrobial resistance (AMR) represents a major threat 
to human health by impeding effective treatment of serious 
infections and leading to increased morbidity, mortality 
and healthcare costs [1]. Acknowledging the implica-
tions of rising AMR, in 2015, the World Health Assembly 
adopted the Global Action Plan on AMR which outlined 
specific actions to address the increase in AMR including 
strengthening AMR surveillance and global data sharing 
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[2]. In response to the Global Action Plan, the World 
Health Organization launched the Global AMR Surveil-
lance System (GLASS).
The 2020 GLASS report emphasizes the persisting geo-
graphic gaps in AMR surveillance with health facilities 
and laboratories from Europe and the Americas contrib-
uting the majority of data. Data from low- and middle-
income countries (LMIC) in Africa and Southeast Asia 
are scarce due to limited laboratory capacity and avail-
ability of microbiological diagnosis [3]. The main chal-
lenges restricting bacterial identification and detection of 
resistance are insufficient laboratory scientists and techni-
cians, stock-outs of laboratory consumables, short shelf 
life of some key reagents, difficulties in supply chains 
management and prohibitive costs [4, 5]. In most LMICs, 
both availability and cost of diagnostic tests limit access 
for a large majority of patients who have most infectious 
conditions treated empirically and with the use of case 
definitions rather than laboratory confirmation. Blood cul-
tures for example are usually restricted to tertiary referral 
hospitals and are not available at lower tier hospitals (i.e. 
district hospitals) and peripheral healthcare facilities [6].
Even at the levels where these tests are available, the 
turnaround time is such that antimicrobials are prescribed 
and consumed before the results are available to influence 
the choice. Limited availability of diagnostics results in 
a lack of AMR surveillance data and non-adaptation of 
empirical treatment to local pathogens and resistance 
profiles. Available data are usually biased towards more 
complex cases treated at referral centres or in private 
healthcare settings, and are not representative of the over-
all burden of resistance, challenging the development of 
locally adapted treatment recommendations.
Two novel ready-to-use culture systems, InTray and 
Compact Dry, may facilitate processing of urine samples 
in low-resource settings particularly in regional and dis-
trict healthcare facilities where fully equipped microbi-
ology laboratories may not be available. These systems 
have particular advantages that may allow for their use in 
lower tier facilities, thus expanding access to microbiol-
ogy services. Urinary tract infections (UTIs) are common 
Gram-negative infections in outpatient settings. Organ-
isms causing UTIs may provide valuable information on 
community-level Gram-negative resistance. Urine samples 
are non-invasive and considered priority specimens for 
AMR surveillance by the WHO-GLASS [3].
The aims of this study were to evaluate the performance 
of InTray COLOREX Screen/ESBL and Compact Dry for 
the detection of uropathogens and of extended-spectrum 
beta-lactamase (ESBL)-producing organisms in urine 
samples from patients presenting with UTI symptoms to 
primary care clinics in Harare.
Methods
Study participants were recruited into the antimicrobial 
resistance in Gram-negative bacteria from Urinary Speci-
mens (ARGUS) study which is an observational cross-
sectional study enrolling adult patients who present with 
suspected UTIs to one of nine participating primary health 
clinics in Harare. The procedures and eligibility for the 
ARGUS study have been described in detail elsewhere [7]. 
Briefly, after obtaining informed consent, demographic 
and medical history was collected using a questionnaire 
and entered directly in an electronic form using the Open 
Data Kit (ODK, www. opend atakit. org). A midstream urine 
sample was collected from each of the study participants. 
If the transportation time to the laboratory was anticipated 
to exceed 4 h, the urine sample was placed in a thermally 
insulated bag containing ice packs.
Culture media
This study used two novel culturing techniques—(1) 
InTrays COLOREX Screen and InTray COLOREX ESBL 
(Biomed Diagnostic, White City, OR, USA) and (2) Com-
pact Dry EC (Nissui Pharmaceutical Co. Ltd., Tokyo, 
Japan)—and compared them to culture on Brilliance UTI 
agar (Oxoid, UK) which is considered the reference stand-
ard [8].
InTrays are ready-to-use commercially available small-
sized agar plates (5-cm diameter for the agar) with chromo-
genic substrates to differentiate between multiple bacterial 
species based on colony colour. InTray COLOREX ESBL 
plates contain, in addition, antimicrobial compounds for 
selective identification of extended-spectrum beta-lactamase 
(ESBL)-producing organisms. InTrays have to be stored at 
2–8 °C and have a shelf life of 6 (InTray COLOREX ESBL) 
to 12 months (InTray COLOREX Screen) [9].
Compact Dry EC is a dehydrated ready-to-use chromo-
genic medium designed for quantifying Escherichia coli 
and coliforms from food products. The media is hydrated 
by sample inoculation and capillary action allows for diffu-
sion of the sample across the plate. The media contains two 
chromogenic enzyme substrates, Magenta-Gal and X-Gluc, 
which enable the differentiation between E. coli (blue) and 
other coliforms (pink). The plastic casing has a grid with 
large and small squares for ease of colony counting. For opti-
mal colony counting, the manufacturer recommends dilut-
ing samples to concentrations of 100 colony forming units 
(CFU)/mL. The media is heat, light and moisture-sensitive 
and is supplied in small opaque pouches containing desic-
cant. The plates are stored at room temperature up to 30 °C 
and have a shelf life of 18 months post-manufacture [10].
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Colony appearance and characteristics of the different 
media are described in Table 1 and additional Figures S1 
and S2.
Sample processing
Following collection, the urine samples were inoculated 
by trained research assistants at the point of care onto the 
InTray COLOREX Screen and ESBL culture plates using 
a cotton swab (one tray per sample). For the Compact Dry 
and Brilliance UTI agar, urine samples were processed at the 
Biomedical Research and Training Institute research labora-
tory. The inoculated culture plates were then transported to 
the laboratory where they were incubated at 37 °C for 24 h. 
The InTrays were read after 24 h by a trained microbiologist. 
Information on the number of CFU, morphology, colour and 
growth was recorded using a standardized form. Because 
InTrays require refrigeration, uninoculated plates had to be 
transported at the end of each working day to the laboratory 
and dispatched again to the clinics on the following day.
For Compact Dry, it was assumed that positive urine 
cultures would have a bacterial concentration of at least 
 103 CFU/mL [11]. To perform colony counts, serial dilu-
tions of 1:10 were performed on the day of sample collec-
tion. The urine samples were diluted up to  106 in sterile 
phosphate-buffered saline and 1 mL each of the  103 and 
 106 dilutions was inoculated on the Compact Dry and 
incubated for 24 h at 37 °C. The optimal dilutions were 
established during a pilot phase and previous use of the 
culture system in our laboratory (unpublished). The plates 
were read by a trained microbiologist and the number of 
CFU and colony appearance was recorded. If colonies 
could not be counted, growth was categorized semi-quan-
titatively into semi-confluent (some individual colonies 
still visible) and confluent growth (individual colonies not 
visible with a change in substrate colour).
Brilliance UTI agar was inoculated at the laboratory 
using 1-µL sterile loops and incubated at 37 °C for 24 h. 
Growth was reported semi-quantitatively into three catego-
ries:  103–104 CFU/mL,  104–105 CFU/mL and >  105 CFU/
mL. All cultures showing growth of >  103 CFU/mL with 
the predominance of uropathogens were considered 
positive.
Antimicrobial susceptibility testing (AST) was done by 
disc diffusion and interpreted according to the EUCAST 
standards [12]. ESBL testing of Enterobacterales was per-
formed according to the EUCAST recommendations [13]. 
Briefly, isolates were screened for the presence of ESBLs 
using cefpodoxime. Isolates positive on the screening test 
underwent confirmation by synergy testing with amoxi-
cillin/clavulanic acid and ceftazidime. Quality control 
for bacterial identification and AST was performed using 
ATCC reference isolates.
Table 1  Colony appearance and product characteristics for the three culture systems used in the study [8–10]
KESC Klebsiella, Enterobacter, Serratia, Citrobacter; RT room temperature. Dehydrated media, supplied in powder form requiring preparation; 
prepared, pre-poured plates as supplied by the manufacturer
Brilliance UTI agar InTray COLOREX Compact Dry EC
E. coli Pink Pink Blue
KESC* Dark blue Blue/turquoise Red-violet (pink)
Proteus group Brown halo Brown halo Yellow–brown
Pseudomonas spp. Brown/green Cream, translucent -
Enterococcus spp. Turquoise Blue/turquoise Inhibited
S. aureus White/cream Golden Inhibited
S. saprophyticus Pink, small Pink, small Inhibited
Other streptococci/staphylococci Non-pigmented/white White Inhibited
Product and use characteristics
  Storage temperature Dehydrated: RT
Prepared: 2–8 °C
2–8 °C RT (< 30 °C)
  Shelf life Dehydrated: ~ 2 years
Prepared: 2 weeks
6–12 months 18 months
  Size/format (mm) Dehydrated: container
Prepared: 85 × 85 × 14
103 × 75 × 8
Agar: 5 cm
Culture media: 5.5 cm
  Number of samples Multiple Single Single
  Preparation required Yes (dehydrated) No No
  Number of samples inoculated 1–6/ plate 1 1
  Sample and volume inoculated Neat urine, 1 µL Neat urine, using a swab Diluted urine  103 and  106; 1 mL
  Location of sample inoculation Laboratory Point of care (clinic) Laboratory
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Experience in using the tests
Research assistants and laboratory staff involved in sample 
processing were asked about the perceived advantages and 
shortcomings of the test systems. The number of times the 
InTray plates were removed from the fridge and dispatched 
to the clinics was recorded to determine if multiple expo-
sures to high temperatures affect the test performance.
Statistical analysis
Descriptive analyses were performed in STATA v.15 (Stata-
Corp, TX, USA). To evaluate test performance, sensitivity 
and specificity with 95% confidence intervals (95% CI) were 
calculated. The correlation between CFUs on Compact Dry 
and growth on Brilliance UTI agar categorized semi-quan-
titatively was evaluated using Spearman’s correlation test.
The study was granted ethics approval by the London 
School of Hygiene and Tropical Medicine (ref. 16,424) 
and by the Medical Research Council of Zimbabwe 
(MRCZ/A/2406).
Results
A total of 431 urine samples were tested using the three 
culture systems. Of those, 17 (3.9%) were contaminated on 
Brilliance UTI agar and were excluded leaving 414 samples 
for the final analysis. The median age of study participants 
was 36 years (IQR 26–46), 263 (63.5%) were female and 
169 (42.7%) were HIV positive. Participant characteristics 
are shown in additional Table S1.
InTray COLOREX Screen for uropathogen detection
Using the Brilliance UTI agar, 98 urine cultures were posi-
tive. Uropathogens identified were 72 E. coli (73.5%), 11 
other Enterobacterales (11.2%), 13 Enterococcus spp. 
(13.3%) and two Staphylococcus aureus (2.0%). Of the 
72 cultures growing E. coli on the Brilliance UTI agar, 64 
showed growth of pink colonies (E. coli) on the InTray COL-
OREX Screen culture plates while eight were positive on 
Brilliance only and six on InTrays only. For other coliforms, 
ten cultures were positive on both Brilliance and InTrays and 
an additional sample was positive on the Brilliance UTI agar 
only (Table 2).
Of the 13 samples that were positive on the Brilliance 
UTI agar for enterococci, nine were also positive for ente-
rococci on the InTray COLOREX Screen cultures. The four 
discordant samples that were positive for enterococci on 
the Brilliance UTI agar had growth of enterococci on the 
InTrays but enterococci were not the dominant organism. 
Conversely, 15 cultures had predominant growth of ente-
rococci on the InTray but were negative on the Brilliance 
UTI agar. The two cultures with growth of S. aureus were 
positive on both culture media.
Using the Brilliance UTI agar as the reference standard 
and a threshold for positivity of  103 CFU/mL, the sensitivity 
of InTray COLOREX Screen for detecting Enterobacterales 
was 89.2% (74/83; 95% CI 80.4–94.9) and the specificity 
was 98.2% (325/331; 95% CI 96.1–99.3). Positive and nega-
tive predictive values were 92.5% (74/80; 95% CI 84.4–97.2) 
and 97.3% (325/334; 95% CI 94.9–98.8), respectively. Test 
performance according to different thresholds for culture 
positivity is shown in Table 3.
Compact Dry EC for uropathogen detection
Of the 83 samples which had growth of Enterobacterales 
on Brilliance UTI agar, 79 had growth on the Compact 
Dry EC of Enterobacterales at the 1:103 dilution and 
58 at the 1:106 dilution. Four samples which were posi-
tive for E. coli on Brilliance were negative on Compact 
Dry and one sample with Proteus spp. was positive on 
Table 2  Comparison between culture results for InTray Screen and Brilliance UTI agar for Enterobacterales 
* Negative cultures, one colony on InTray ESBL but not on Screen (n = 2); mixed growth of organisms with colonies on InTray but < 5 colonies 
(n = 3); #3/6 discordant cultures with a positive InTray also had growth with low colony count on Compact Dry. Gram-positive organisms (Ente-
rococcus spp., n = 13 and S. aureus, n = 2) were not included in the table as their growth is inhibited on the Compact Dry media







 >  105 CFU/mL
InTray COLOREX Screen Negative (or 1–4 colonies)* 325 4 3 2 334
Positive
  5–49 colonies 4 5 3 0 12
  50–100 colonies 0 1 0 1 2
  Confluent growth 2 0 8 56 66
Total 331 10 14 59 414
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Compact Dry only (Table 4). The sensitivity and speci-
ficity for uropathogen detection were 95.2% (79/83; 95% 
CI 88.1–98.7) and 99.7% (330/331; 95% CI 98.3–100), 
respectively, using a threshold for urine culture positiv-
ity of  103 CFU/mL on the Brilliance UTI agar (Table 3). 
Positive and negative predictive values were 98.8% 
(79/80; 95% CI 93.2–99.9) and 98.8% (330/334; 95% CI 
97.0–99.7). Using the 1:103 dilution, 55/80 (69%) of posi-
tive samples on Compact Dry had semi-confluent or con-
fluent growth and therefore colony counts could not be 
performed. While the 1:103 dilution had a better sensitiv-
ity, the higher dilution allowed for colony counts. There 
was a strong correlation between CFUs determined using 
the Compact Dry and the semi-quantitative assessment 
on Brilliance UTI agar (Spearman’s rho 0.924, p < 0.001; 
Fig. 1).
InTray COLOREX ESBL for the diagnosis 
of cephalosporin‑resistant organisms
InTray COLOREX ESBL culture results were available for 
413 samples. Synergy testing for the presence of ESBLs was 
positive in 22/24 isolates tested (E. coli, n = 20; other coli-
forms, n = 2). Of the 22 ESBL-positive organisms using con-
ventional methods, 21 were positive on InTray COLOREX 
ESBL. Two samples were positive on InTray COLOREX 
ESBL only: negative on Brilliance UTI agar (n = 1); nega-
tive screening test for ESBL using cefpodoxime (n = 1). One 
sample which was ESBL positive using conventional meth-
ods and negative on InTray had growth of a single colony 
on InTray. The sensitivity of the InTray COLOREX ESBL 
culture plates for the detection of ESBL-producing organ-
isms was 95.5% (21/22; 95% CI 77.2–99.9) and specificity 
was 99.5% (400/402; 95% CI 98.2–99.9%).
Table 3  Performance for Compact Dry EC and InTray Screen in the detection of Enterobacterales compared with Brilliance UTI agar and using 
different thresholds for culture positivity on Brilliance agar
NPV negative predictive value; PPV positive predictive value
Cut-off on Bril-
liance agar
Sensitivity (95% CI) Specificity (95% CI) PPV (95% CI) NPV (95% CI)
Compact Dry at 
1:103 dilution
103 95.2 (88.1–98.7) 99.7 (98.3–100) 98.8 (93.2–99.9) 98.8 (97.0–99.7)
104 98.6 (92.6–100) 97.7 (95.4–99.0) 90.0 (81.2–95.6) 99.7 (98.3–99.9)
105 100 (93.9–100) 94.1 (91.1–96.3) 73.8 (62.7–83.0) 100 (98.9–100)
InTray COLO-
REX Screen
103 89.2 (80.4–94.9) 98.2 (96.1–99.3) 92.5 (84.4–97.2) 97.3 (94.9–98.8)
104 93.2 (84.7–97.7) 96.5 (93.9–98.2) 85.0 (75.2–92.0) 98.5 (96.5–99.5)
105 96.6 (88.3–100) 93.5 (90.4–95.8) 71.3 (60.0–80.8) 99.4 (97.9–99.9)
Table 4  Comparison between culture results for Compact Dry and Brilliance UTI agar for Enterobacterales 
Cultures which showed contamination on Brilliance UTI agar were excluded; *this culture had mixed growth and one of the organisms was Pro-
teus which had confluent growth on the Compact Dry due to swarming; #for the 1:106 dilution, this category included growth of 1–49 colonies









 >  105 CFU/
mL
Compact Dry EC at 1:103 dilution Negative (or 1–4 colonies) 330 3 1 0 334
5–49 colonies 0 6 3 2 11
50–250 colonies 0 1 4 2 7
Semi-confluent growth or > 250 colonies 0 0 6 18 24
Confluent growth 1* 0 0 37 38
Compact Dry EC at 1:106 dilution Negative 331 8 11 6 356
1–49  colonies# 0 2 3 32 37
50–250 colonies 0 0 0 18 18
Semi-confluent growth or > 250 colonies 0 0 0 2 2
Confluent growth 0 0 0 1 1
Total 331 10 14 59 414
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Reported experience of staff using the tests
Research assistants who inoculated the urine samples onto 
InTrays at point of care (n = 9) reported that overall the diag-
nostic device was easy to use, and they reported no chal-
lenges inoculating the agar in the field. The procedure was 
simple and was not time-consuming. The main challenge 
was the requirement for the InTrays to be refrigerated and 
thus InTrays not used on a particular day had to be trans-
ported daily from the laboratory to the clinics. In order to 
decrease the number of times the InTrays were transported 
between the laboratory and clinics, a limited number of 
InTrays was issued to each clinic every day. This meant 
that research assistants sometimes ran out of InTrays if the 
number of participants enrolled outnumbered the number 
of InTrays sent to the clinic. The median number of times 
InTrays were sent to the clinics was 2 (IQR 1–4). The num-
ber of times an InTray was transported to a clinic did not 
affect sensitivity of the culture system.
Laboratory staff (n = 2) reported on the processing, read-
ing and interpretation of the test results. Both InTray and 
Compact Dry plates are relatively small in size minimizing 
incubator space requirements. For both systems, cultures 
were very easy to read and interpret. A major advantage 
compared to the UTI Brilliance agar was that InTrays and 
Compact Dry were ready to use and did not require media 
preparation and autoclaving. In LMICs, electricity supplies 
can be unreliable and generators cannot always provide a 
sufficient power supply for high-energy processes such as 
autoclaving. In the study setting, media preparation and 
autoclaving could not be done during power-cuts. However, 
Compact Dry was more difficult to inoculate because they 
required sequential dilutions which were performed in the 
laboratory.
Discussion
Both novel culture systems performed well in detecting 
uropathogens compared to Brilliance UTI chromogenic 
media, the reference standard. The diagnostic systems were 
easy to use and study staff required minimal training for 
inoculation and reading. Furthermore, InTray COLOREX 
ESBL plates showed a high sensitivity and specificity for 
the detection of ESBL Enterobacterales making them an 
attractive tool for AMR surveillance in LMICs. Because 
the system selectively identifies ESBL-producing organ-
isms from primary specimens, it can reduce time to results 
when used for diagnosis, which in turn may reduce time to 
appropriate therapy.
Conventional culture media have to be prepared fre-
quently and require refrigeration which may be challeng-
ing in LMICs due to unreliable electricity supplies and 
equipment maintenance. Preparation of dehydrated media 
requires autoclaving and quality control of every prepared 
batch. InTray and Compact Dry are pre-prepared culture 
plates which are smaller than conventional plates and have 
an extended shelf life bypassing some of the shortcomings 
associated with conventional cultures. Both systems are 
based on chromogenic identification. Although chromo-
genic media for bacterial identification are not novel and 
have been in use for more than two decades [14], media 
Fig. 1  Comparison of semi-
quantitative bacterial growth on 
Brilliance UTI agar and colony 
counts using Compact Dry
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prepared in-house from dehydrated powder usually expire 
within 2 weeks [8]. InTray COLOREX Screen and ESBL are 
stable for 6–12 months and Compact Dry EC for 18 months 
post-manufacture. Furthermore, Compact Dry media does 
not require refrigeration and can be stored at temperatures 
up to 30° which is an added advantage when used in LMICs.
The Compact Dry system has been designed for deter-
mining bacterial contamination of food [15]. One previous 
study from Japan reported good sensitivity of the Compact 
Dry when used to investigate UTIs in humans, but the sam-
ple size was small (n = 25) [16]. Because the Compact Dry 
is a highly sensitive culture system and positive urine cul-
tures usually have high bacterial loads, the urine samples 
were diluted prior to inoculation. For the purpose of this 
study, serial dilutions were performed. However, the proce-
dures could be simplified by performing a single dilution at 
a higher factor (for example by diluting 1-µL sample into a 
1 mL of sterile solution). A volume of 1 mL is required in 
order to rehydrate the dry culture media. Although of limited 
clinical significance, Compact Dry allows for colony counts 
which can be used to estimate bacterial load in samples. In 
this study, colony counts using the Compact Dry correlated 
well with the semi-quantitative results on Brilliance UTI 
agar.
Gram-positive pathogens such as Enterococcus spp. and 
S. saprophyticus account for 15% of uncomplicated UTIs 
[17]. While InTrays can detect these pathogens, Compact 
Dry ECs can only be used for the detection of Enterobac-
terales and do not support growth of Gram-positive organ-
isms. Enterococci were detected more frequently using 
InTrays than on conventional media. This may suggest an 
under-diagnosis of enterococcal infections using conven-
tional media although growth of enterococci from midstream 
urine samples may not necessarily reflect the presence of 
enterococci in the urinary bladder [18] and therefore results 
should be interpreted with caution considering the patient’s 
medical history.
Cultures that were positive on InTray only may be 
explained by inoculation of a larger sample volume using 
swabs compared to 1-µL inoculation on Brilliance UTI agar. 
Furthermore, immediate inoculation of the sample may have 
prevented loss of bacterial viability during transport. False-
negative Compact Dry results were only observed for urine 
samples with lower bacterial load classified as  103–104 
CFUs on the Brilliance UTI agar. These urine samples may 
have shown growth on Compact Dry if the urine had been 
less diluted (<  103). One sample showed confluent growth 
for Proteus spp. on the Compact Dry but was negative 
on Brilliance UTI agar. This was due to the inhibition of 
swarming on the Brilliance agar but not on Compact Dry.
This is the first study evaluating the performance of the 
InTray and Compact Dry culture systems for the diagnosis 
of UTI. We acknowledge that the study is limited by its 
relatively small sample size and low proportion of positive 
urine cultures.
Our findings show good performance of the novel 
culture systems for the detection of uropathogens and 
ESBL-producing organisms. These systems may simplify 
laboratory workflow, reduce technician processing time 
and facilitate procurement and stock management. Both 
systems have potential to expand and decentralize labora-
tory testing. Use of the systems in sentinel clinical sites 
may enhance understanding of pathogens and AMR bur-
den in LMICs. Further research is needed to demonstrate 
cost-effectiveness and feasibility of wider implementation 
of these systems for AMR surveillance, and potentially 
impact on patient outcomes in LMICs.
Supplementary Information The online version contains supplemen-
tary material available at https:// doi. org/ 10. 1007/ s10096- 021- 04312-4.
Acknowledgements This work was supported by the Foundation for 
Innovative New Diagnostics (FIND) who provided the InTray COLO-
REX Screen and ESBL for evaluation.
Author contribution IDO and KK conceived the study idea and 
planned the study. WE, NM, JP and CF contributed to the study idea. 
NM, JP, CF, PC and KPEM provided support with the resources needed 
for the study. SY, RAF and HH provided support with conducting the 
study. IDO and MC conducted the laboratory testing and interpretation 
of results. IDO and KK analysed and interpreted the data, and drafted 
the initial manuscript. WE, MC, NM, JP, SY, RAF, HH, PC, KPEM 
and PM reviewed and provided feedback on the initial manuscript. All 
authors read and approved the final manuscript.
Funding IDO received funding though the Wellcome Trust Clinical 
PhD Programme awarded to the London School of Hygiene and Tropi-
cal Medicine (grant number 203905/Z/16/Z). The funders had no role 
in study design, data collection and interpretation, or the decision to 
submit the work for publication. The study was funded by UK aid from 
the UK government; the views expressed, however, do not necessarily 
reflect the UK government’s official policies. FIND was supported by 
UK aid from the British people for the acquisition of the InTrays which 
were used in the study.
Data availability The datasets generated and/or analysed during the 
current study are available in the Data Compass (LSHTM) repository, 
https:// datac ompass. lshtm. ac. uk/ 1997/. All data generated or analysed 
during this study are included in this published article and its supple-
mentary information files.
Code availability Not applicable.
Declarations 
Ethics approval The study was performed in accordance with the 
ethical standards as laid down in the 1964 Declaration of Helsinki 
and its later amendments or comparable ethical standards. The study 
was granted ethics approval by the London School of Hygiene and 
Tropical Medicine (ref. 16424) and by the Medical Research Council 
of Zimbabwe (MRCZ/A/2406).
 European Journal of Clinical Microbiology & Infectious Diseases
1 3
Consent to participate All study participants provided written 
informed consent prior to study participation.
Consent for publication Not applicable.
Competing interests The authors declare no competing interests.
Open Access This article is licensed under a Creative Commons Attri-
bution 4.0 International License, which permits use, sharing, adapta-
tion, distribution and reproduction in any medium or format, as long 
as you give appropriate credit to the original author(s) and the source, 
provide a link to the Creative Commons licence, and indicate if changes 
were made. The images or other third party material in this article are 
included in the article’s Creative Commons licence, unless indicated 
otherwise in a credit line to the material. If material is not included in 
the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will 
need to obtain permission directly from the copyright holder. To view a 
copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/.
References
 1. Cosgrove SE (2006) The relationship between antimicrobial 
resistance and patient outcomes: mortality, length of hospital stay, 
and health care costs. Clin Infect Dis 42 Suppl 2:S82-89
 2. World Health Organization (2015) Global action plan on antimi-
crobial resistance. WHO. http:// www. wpro. who. int/ entity/ drug_ 
resis tance/ resou rces/ global_ action_ plan_ eng. pdf. Accessed 15 Jan 
2021
 3. Global antimicrobial resistance surveillance system (GLASS) 
report: early implementation (2020). Geneva: World Health 
Organization. Licence: CC BY-NC-SA 3.0 IGO. Available from: 
https:// www. who. int/ glass/ resou rces/ publi catio ns/ early- imple 
menta tion- report- 2020/ en/.  Accessed 15 Jan 2021
 4. Boeras DI, Peeling RW, Onyebujoh P, Yahaya AA, Gumede-
Moeletsi HN, Ndihokubwayo JB (2016) The WHO AFRO exter-
nal quality assessment programme (EQAP): linking laboratory 
networks through EQA programmes. Afr J Lab Med 5(2):560
 5. Usuf E, Mackenzie G, Sambou S, Atherly D, Suraratdecha C 
(2016) The economic burden of childhood pneumococcal diseases 
in The Gambia. Cost Eff Resour Alloc 14:4
 6. Crump JA, Heyderman RS (2015) A perspective on invasive Sal-
monella disease in Africa. Clin Infect Dis 61 Suppl 4:S235-240
 7. Olaru ID, Yeung S, Ferrand RA, Stabler R, Chonzi P, Mabey D 
et al (2020) Antimicrobial resistance in gram-negative bacteria 
from urinary specimens: a study of prevalence, risk factors and 
molecular mechanisms of resistance (ARGUS) in Zimbabwe – a 
study protocol. Wellcome Open Research 5:140
 8. Brilliance UTI culture media (Oxoid). Product information. Avail-
able from http:// www. oxoid. com/ uk/ blue/ prod_ detail/ prod_ detail. 
asp? pr= cm094 9&c= uk& lang= en.  Accessed 15 Jan 2021
 9. InTray COLOREX Screen and ESBL product information. 
Available from https:// biome ddiag nosti cs. com/ prepa red- cultu 
re- media/ clini cal- micro biolo gy/ catal og/ hospi tal- acqui red- infec 
tions.  Accessed 15 Jan 2021
 10. Compact Dry EC Product information sheet and instructions for 
use. Available from https:// catal og. hardy diagn ostics. com/ cp_ 
prod/ Conte nt/ hugo/ Compa ctDry EC. pdf.  Accessed 15 Jan 2021
 11. Bonkat G, Pickard R, Bartoletti R et al EAU guidelines on urologi-
cal infections. Arnhem, the Netherlands: European Association 
of Urology. Available from https:// uroweb. org/ wp- conte nt/ uploa 
ds/ EAU- Guide lines- on- Urolo gical- Infec tions- 2018- large- text. 
pdf.  Accessed 15 Jan 2021.
 12. The European Committee on Antimicrobial Susceptibility Testing. 
Breakpoint tables for interpretation of MICs and zone diameters. 
Version 8.1, 2018. Available from https:// www. eucast. org/ filea 
dmin/ src/ media/ PDFs/ EUCAST_ files/ Break point_ tables/ v_8. 1_ 
Break point_ Tables. pdf.  Accessed 15 Jan 2021
 13. EUCAST guidelines for detection of resistance mechanisms and 
specific resistances of clinical and/or epidemiological importance 
Version 2.01 July 2017. Available from https:// eucast. org/ resis 
tance_ mecha nisms/.  Accessed 15 Jan 2021
 14. Samra Z, Heifetz M, Talmor J, Bain E, Bahar J (1998) Evaluation 
of use of a new chromogenic agar in detection of urinary tract 
pathogens. J Clin Microbiol 36(4):990–994
 15. Mizuochi S, Nelson M, Baylis C, Jewell K, Green B, Limbum 
R, Fernandez MC, Salfinger Y, Chen Y (2016) Matrix exten-
sion study: validation of the Compact Dry TC method for enu-
meration of total aerobic bacteria in selected foods. J AOAC Int 
99(2):461–468
 16. Horii T, Morita M, Kameno Y, Kanno T, Maekawa M (2002) 
Comparison of a new system (Compactdry SCD) with conven-
tional methods for quantitative urine cultures. Lett Appl Microbiol 
35(6):499–503
 17. Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ (2015) 
Urinary tract infections: epidemiology, mechanisms of infection 
and treatment options. Nat Rev Microbiol 13(5):269–284
 18. Hooton TM, Roberts PL, Cox ME, Stapleton AE (2013) Voided 
midstream urine culture and acute cystitis in premenopausal 
women. N Engl J Med 369(20):1883–1891
Publisher’s note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
